Fig. 2

Neoantigen prediction and validation workflow. Left panel corresponds to the workflow of in silico neoantigen prediction. Next, putative neoantigens obtained from neoantigen prediction are subject to ex vivo validation where various techniques, such as mass spectrometry, Elispot and MHC Tetramer are used for selecting presented and immunogenic neoantigens for clinical applications